Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fingolimod
Drug ID BADD_D02464
Description Multiple sclerosis or MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod is currently being studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. Phase 2 clinical trials are currently underway and completion is expected in July 2020.[L12654]
Indications and Usage Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Marketing Status Not Available
ATC Code L04AA27
DrugBank ID DB08868
KEGG ID D10001
MeSH ID D000068876
PubChem ID 107970
TTD Drug ID D07UHS
NDC Product Code 54893-0026; 65035-201
Synonyms Fingolimod Hydrochloride | 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride | FTY-720 | FTY 720 | FTY720 | Gilenya | Gilenia | Fingolimod
Chemical Information
Molecular Formula C19H33NO2
CAS Registry Number 162359-55-9
SMILES CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral infarction24.04.06.002; 17.08.01.004--Not Available
Cerebrospinal fluid leakage17.02.05.001; 12.01.10.0040.001737%
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Cerebrovascular disorder17.08.02.002; 24.03.05.0020.000604%Not Available
Cervical dysplasia21.06.01.0020.027213%Not Available
Cervicitis21.14.05.001; 11.01.10.0040.001158%
Cervicobrachial syndrome17.10.02.001; 15.01.04.0020.001737%Not Available
Cervix carcinoma21.06.02.001; 16.12.01.0010.019107%Not Available
Cervix disorder21.06.01.0030.003474%Not Available
Cheilitis23.03.03.025; 07.05.01.001--
Chest discomfort02.02.02.009; 22.02.08.001; 08.01.08.0190.104218%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.141853%Not Available
Chest X-ray abnormal13.19.02.0010.001737%Not Available
Chills15.05.03.016; 08.01.09.0010.035897%
Chloasma23.05.01.001; 18.08.02.0020.001158%Not Available
Choking22.02.05.0010.006948%Not Available
Cholangitis09.02.01.002--Not Available
Cholangitis sclerosing10.04.09.002; 09.02.01.0030.002316%Not Available
Cholecystitis09.03.01.0010.005211%
Cholecystitis acute09.03.01.003--Not Available
Cholelithiasis09.03.01.0020.013317%Not Available
Cholestasis09.01.01.001--Not Available
Choluria20.02.01.0210.001737%Not Available
Choreoathetosis17.01.01.0030.001158%Not Available
Chorioretinitis11.01.06.010; 06.04.06.0030.001737%Not Available
Choroiditis06.04.06.0040.001158%Not Available
Chromatopsia06.02.05.0010.003474%Not Available
Chromaturia20.02.01.0020.012159%
Chronic lymphocytic leukaemia16.01.06.001; 01.10.06.001--Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 63 Pages